European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New publication alert!
The results of the EORTC-1560-GITCG (ILOC) multicentre single-arm phase II study are now published in ESMO Open.
This study explored the combination of local ablative therapy combined with immunotherapy (durvalumab + tremelimumab) in patients with unresectable liver metastases from metastatic colorectal cancer.
The trial did not demonstrate anti-tumour activity of the combination in locally untreated liver colorectal metastases and emphasises the need to develop more effective immunotherapeutic strategies for metastatic colorectal cancer with liver involvement.